Double-Dose strategy aims to wipe out cancer cells in aggressive blood cancer
NCT ID NCT06207799
Summary
This study is testing if a drug called elranatamab can help control high-risk multiple myeloma when given both before and after a patient's own stem cell transplant. The goal is to see if this approach can eliminate any remaining cancer cells and keep the disease from returning. The trial will enroll 40 adults with newly diagnosed, high-risk multiple myeloma who are eligible for a transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.